NanoViricides (NNVC) 10-Q 15 May 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2017	May 15, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		63,072,000

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2017	Jun. 30, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 16,155,085	$ 24,162,185
Prepaid expenses	217,281	219,458
Prepaid expenses -related party	370,187	0
Total Current Assets	16,742,553	24,381,643
PROPERTY AND EQUIPMENT
Property and equipment	13,730,203	13,611,583
Accumulated depreciation	(2,340,146)	(1,850,816)
Property and equipment, net	11,390,057	11,760,767
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(73,688)	(67,487)
Trademark and patents, net	385,266	391,467
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	58,274	96,026
Total Other Assets	61,789	99,541
Total Assets	28,579,665	36,633,418
CURRENT LIABILITIES:
Accounts payable	112,706	96,524
Accounts payable - related parties	0	767,454
Debenture payable - Series B, net of discount	0	5,474,737
Derivative liability - Series B debentures	0	203,030
Accrued expenses	52,270	35,602
Deferred interest payable - current portion	166,667	166,667
Total Current Liabilities	331,643	6,744,014
LONG TERM LIABILITIES:
Deferred interest payable - long term portion	41,666	166,667
Total Long Term Liabilities	5,842,274	6,841,190
Total Liabilities	6,173,917	13,585,204
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 63,072,333 and 58,179,699 shares issued and outstanding at March 31, 2017 and June 30, 2016, respectively	63,072	58,179
Additional paid-in capital	94,909,056	87,810,145
Accumulated deficit	(72,570,721)	(64,824,201)
Total Stockholders' Equity	22,405,748	23,048,214
Total Liabilities and Stockholders' Equity	28,579,665	36,633,418
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability	2,017,476	3,197,182
Series C Debenture [Member]
LONG TERM LIABILITIES:
Debenture payable	3,732,816	3,133,668
Derivative liability	50,316	343,673
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 4,341,028 and 4,091,094 shares issued and outstanding, at March 31, 2017 and June 30, 2016, respectively	$ 4,341	$ 4,091

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	63,072,333	58,179,699
Common stock, shares, outstanding	63,072,333	58,179,699
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,500,000	8,500,000
Preferred stock, shares issued	4,341,028	4,091,094
Preferred stock, shares outstanding	4,341,028	4,091,094

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
OPERATING EXPENSES
Research and development	$ 1,559,202	$ 1,067,495	$ 4,272,339	$ 3,427,068
General and administrative	1,056,512	980,731	3,081,442	2,936,510
Total operating expenses	2,615,714	2,048,226	7,353,781	6,363,578
LOSS FROM OPERATIONS	(2,615,714)	(2,048,226)	(7,353,781)	(6,363,578)
OTHER INCOME (EXPENSE):
Interest income	17,959	39,116	43,870	43,378
Interest expense on convertible debentures	(165,767)	(301,115)	(655,767)	(791,115)
Discount on convertible debentures	(297,662)	(362,993)	(1,124,411)	(1,046,663)
Loss on extinguishment of debt	(332,524)	0	(332,524)	0
Change in fair value of derivatives	255,031	(2,318,453)	1,676,093	(915,938)
Other (expense) income	(522,963)	(2,943,445)	(392,739)	(2,710,338)
LOSS BEFORE INCOME TAX PROVISION	(3,138,677)	(4,991,671)	(7,746,520)	(9,073,916)
INCOME TAX PROVISION	0	0	0	0
NET LOSS	$ (3,138,677)	$ (4,991,671)	$ (7,746,520)	$ (9,073,916)
NET LOSS PER COMMON SHARE
- Basic (in dollars per share)	$ (0.05)	$ (0.09)	$ (0.13)	$ (0.16)
- Diluted (in dollars per share)	$ (0.05)	$ (0.09)	$ (0.13)	$ (0.16)
Weighted average common shares outstanding
- Basic (in shares)	61,002,941	57,836,770	59,115,786	57,565,406
- Diluted (in shares)	61,002,941	57,836,770	59,115,786	57,565,406

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 9 months ended Mar. 31, 2017 - USD ($)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AccumulatedDeficit [Member]
Balance at Jun. 30, 2016	$ 23,048,214	$ 4,091	$ 58,179	$ 87,810,145	$ (64,824,201)
Balance (in shares) at Jun. 30, 2016		4,091,094	58,179,699
Common shares issued for employee compensation	82,145	$ 0	$ 72	82,073	0
Common shares issued for employee compensation (in shares)		0	71,430
Common shares issued upon conversion of Series B Debenture	5,332,524	$ 0	$ 4,335	5,328,189	0
Common shares issued upon conversion of Series B Debenture (in shares)		0	4,335,386
Series A Preferred Shares issued for employee stock compensation	1,101,661	$ 250	$ 0	1,101,411	0
Series A Preferred Shares issued for employee stock compensation (in shares)		249,934	0
Common shares issued for consulting and legal services rendered	81,000	$ 0	$ 60	80,940	0
Common shares issued for consulting and legal services rendered (in shares)		0	59,900
Warrants issued to Scientific Advisory Board	32,462	$ 0	$ 0	32,462	0
Common shares issued for debenture interest	440,512	$ 0	$ 401	440,111	0
Common shares issued for debenture interest (in shares)		0	401,087
Common shares issued for Directors services	33,750	$ 0	$ 25	33,725	0
Common shares issued for Directors services (in shares)		0	24,831
Net loss	(7,746,520)	$ 0	$ 0	0	(7,746,520)
Balance at Mar. 31, 2017	$ 22,405,748	$ 4,341	$ 63,072	$ 94,909,056	$ (72,570,721)
Balance (in shares) at Mar. 31, 2017		4,341,028	63,072,333

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,746,520)	$ (9,073,916)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	1,101,661	547,946
Common shares issued as compensation and for services	196,895	143,050
Common shares issued for interest	440,512	493,334
Warrants granted to Scientific Advisory Board	32,462	29,422
Warrants issued for Series B Debenture Interest	0	56,115
Depreciation	489,330	488,997
Amortization	6,201	6,202
Change in fair value of derivative liability	(1,676,093)	915,938
Amortization of debt discount on convertible debentures	1,124,411	1,046,663
Loss on extinguishment of Series B Debenture	332,524	0
Changes in operating assets and liabilities:
Prepaid expenses	2,177	(100,064)
Prepaid expenses- related party	(370,187)	0
Other assets	37,752	27,341
Accounts payable	16,182	(17,657)
Accounts payable - related party	(767,454)	64,669
Accrued expenses	16,668	49,854
Deferred interest payable	(125,001)	(125,000)
NET CASH USED IN OPERATING ACTIVITIES	(6,888,480)	(5,447,105)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(118,620)	(424,267)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of Series B Debentures payable	(1,000,000)	0
NET CHANGE IN CASH AND CASH EQUIVALENTS	(8,007,100)	(5,871,372)
Cash and cash equivalents at beginning of period	24,162,185	31,467,748
Cash and cash equivalents at end of period	16,155,085	25,596,376
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	492,434	791,115
NON CASH FINANCING AND INVESTING ACTIVITIES:
Common shares issued for debenture payment	5,000,000	0
Common Stock issued upon cashless exercise of stock options	0	313
Depreciation due to decommissioning of West Haven, CT facilities	$ 0	$ 332,476

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. was incorporated under the laws of the State of Colorado July 25, 2000 Edot-com.com . May 12, 2005 ., On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005. Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 100,000,000 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. For further details, see Note 4. On February 15, 2010 the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 (adjusted for the 3.5 to 1 reverse split) The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. 2,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2016 filed with the SEC on September 16, 2016. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 filed on September 16, 2016. Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2017 March 31, 2016 Warrants 6,662,428 6,599,552 Total potentially outstanding dilutive common shares 6,662,428 6,599,552 In addition, the Company has issued Convertible Debentures to investors. At March 31, 2017, pursuant to the redemption provisions of the Company’s Series C Convertible Debenture (the “Series C Debenture”), the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the “Redemption Warrants”, and collectively with (i) – (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. At March 31, 2017, the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381 The Company has also issued 4,341,028 3.5 60% or less 15,193,598 For the three months ended For the Nine months ended March 31, March 31, 2017 2016 2017 2016 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Basic loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Add: Income impact of assumed conversion of Debentures - - - - Net loss attributable to common stockholders plus assumed conversions $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Incremental shares from assumed conversions of Debentures payable - - - - Denominator for diluted weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Diluted loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16) Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three and nine months ended March 31, 2017 because their inclusion is anti-dilutive. Additionally, the Series A Preferred shares are contingently convertible instruments, where the contingency is not based upon the price of the Company’s stock or the convertible instruments. The necessary conditions for conversion (see above) have not been satisfied and the potential shares are not included pursuant to ASC 260-10-55-44. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company is currently in the process of assessing the impact of the ASU on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures.

Financial Condition

Financial Condition	9 Months Ended
	Mar. 31, 2017
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3 - Financial Condition The Company’s financial statements for the interim period ended March 31, 2017 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at March 31, 2017 of $ 72,570,721 16,155,085 6 5,000,000 January 31, 2017 4,335,386 0.001 1,000,000 332,524 While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds. The Company has sufficient capital to continue its business for more than one year, at the current rate of expenditure.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and Director Eugene Seymour CEO, significant stockholder, Director TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder Milton Boniuk, MD Director and significant stockholder For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2017 2016 2017 2016 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 1,589 $ 8,022 $ 19,584 $ 22,670 As of March 31, June 30, 2017 2016 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs, as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ - $ 767,454 March 31, June 30, 2017 2016 Prepaid Expenses – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company is obligated to submit payment equivalent of two months of expenses to TheraCour. This payment is provided to fund expenses incurred by TheraCour on our behalf but have not been billed to the Company. The prepayment net of any accounts payable due to TheraCour Pharma Inc. on the reporting date was $ 370,187 $ - For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2017 2016 2017 2016 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2017 and June 30, 2016 $ 635,591 $ 751,203 $ 2,475,707 $ 2,763,817 As of March 31, June 30, Debentures Payable to a Director 2017 2016 Series B Convertible Debentures - Milton Boniuk $ - $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Debentures Payable to a Director $ 5,000,000 $ 9,000,000 As of March 31, June 30, Debenture Interest Payable to a Director 2017 2016 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 41,666 166,667 Total Debenture Interest Payable to a Director $ 208,333 $ 333,334 Coupon interest expense on the Series B Debentures to two holders controlled by Dr. Milton Boniuk for the three months ended March 31, 2017 and 2016 was $ 27,178 80,000 187,178 240,000 Coupon interest expense on the Series C Debentures to Dr. Milton Boniuk for the three months ended March 31, 2017 and 2016 was $ 125,000 125,000 375,000 375,000

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment March 31, June 30, 2017 2016 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 48,486 46,897 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,419,708 5,302,677 Total Property and Equipment 13,730,203 13,611,583 Less Accumulated Depreciation (2,340,146) (1,850,816) Property and Equipment, Net $ 11,390,057 $ 11,760,767 Depreciation expense for the three months ended March 31, 2017 and 2016 was $ 163,611 163,511 489,330 488,997

Trademark and Patents

Trademark and Patents	9 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents March 31, June 30, 2017 2016 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (73,688) (67,487) Trademarks and Patents, Net $ 385,266 $ 391,467 Amortization expense amounted to $ 2,067 2,067 6,201 6,204

Convertible Debentures and Deri

Convertible Debentures and Derivatives	9 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 - Convertible Debentures and Derivatives Debentures - Series B On February 1, 2013, the Company raised gross proceeds of $ 6,000,000 4,000,000 4 8 13,589 40,000 27,178 80,000 173,589 200,000 107,178 160,000 97,999 101,558 571,429 571,433 3.50 7 The following table presents the balance of the Series B Debenture payable, net of discount at June 30, 2016. The Series B debentures matured on February 1, 2017, as described further below. The debt discount has been amortized to interest expense over the term of the debenture: June 30, 2016 Proceeds $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) 3,264,690 Accumulated amortization of debt discount 2,210,047 Debenture payable - Series B, net $ 5,474,737 The Company recognized amortization of the discount as an additional interest charge to “Discount on convertible debentures” for the three month periods ended March 31, 2017 and 2016, in the amounts of $ 89,165 196,074 525,263 570,505 The debenture contained embedded derivatives that were not clearly and closely related to the host instrument. The embedded derivatives were bifurcated from the host debt instrument and treated as a liability. The single compound embedded derivative features valued include the: 1. Principal conversion feature at maturity based on fixed conversion price subject to standard adjustments. 2. Redemption additional interest and Redemption Warrants offering. 3. Additional Interest Shares and Interest Warrants. The Company used a lattice model that values the compound embedded derivatives bifurcated from the Series B Convertible Debenture based on a probability weighted discounted cash flow model at January 31, 2017 and June 30, 2016. The following assumptions were used for the valuation of the compound embedded derivative at January 31, 2017 and June 30, 2016: ⋅ The balance of the Series B Convertible Debenture was $ 6,000,000 ⋅ The underlying stock price was used as the fair value of the common stock. The warrant value with the $ 3.50 1.60 3.50 ⋅ The projected annual volatility was based on the Company historical volatility: 1 year 6/30/2016 83 ⋅ An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Company would redeem the debentures projected initially at 0 1.0 20.0 ⋅ The Holder would automatically convert the interest if the Company was not in default and its shares value would be equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. ⋅ The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.99 ⋅ Even though the shares are restricted, the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series B Convertible Debenture at January 31, 2017 and June 30, 2016 was $ 0 203,030 The Company’s Series B Convertible Debenture, in the amount of $ 6 5,027,178 4,359,652 5,000,000 1.1533 27,178 4,335,386 24,266 1,000,000 332,524 1.23 5,332,524 5,000,000 Debenture - Series C On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 0.001 5.25 500,000 166,667 125,000 41,667 125,000 41,667 250,000 83,334 149,478 69,736 303,088 211,220 5.25 952,381 5.25 7 619,048 6.05 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 The Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amount of $ 208,497 166,919 599,148 570,505 March 31, June 30, 2017 2016 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 1,764,541 1,165,393 Debenture payable - Series C, net $ 3,732,816 $ 3,133,668 The Company uses a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at March 31, 2017 and June 30, 2016. The following assumptions were used for the valuation of the compound embedded derivative at March 31, 2017 and June 30, 2016: ⋅ The balance of the Series C Convertible Debenture as of March 31, 2017 and June 30, 2016 is $ 5,000,000 ⋅ The underlying stock price was used as the fair value of the common stock; The stock price increased to $ 1.12 6.05 1.60 6.05 ⋅ The projected annual volatility was based on the Company historical volatility: 1 year 3/31/17 70 6/30/16 83 ⋅ An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Holder would automatically convert the interest if the Company was not in default and its share value was equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. ⋅ The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.99 ⋅ Even though the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at March 31, 2017 and June 30, 2016 was $ 50,316 343,673

Equity Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 - Equity Transactions On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 74,317 222,960 77,336 232,008 341,460 On July 21, 2015, the Board of Directors approved a new employment agreement with Dr. Eugene Seymour, the Company’s Chief Executive Officer. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 74,317 222,960 77,336 232,008 341,460 For the three and nine months ended March 31, 2017, the Company’s Board of Directors authorized the issuance of 71,430 82,145 For the three and nine months ended March 31, 2017, the Company’s Board of Directors authorized the issuance of 234,502 249,934 597,694 655,763 Date Shares Value 7/31/2016 2,572 $ 11,439 8/31/2016 2,572 11,978 9/30/2016 2,572 10,847 10/31/2016 2,572 9,591 11/30/2016 2,572 7,631 12/31/2016 2,572 6,583 1/25/2017 200,000 512,984 1/31/2017 2,572 6,231 2/28/2017 2,572 6,357 3/3/2017 26,786 65,629 3/31/2017 2,572 6,493 249,934 $ 655,763 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company. A “Change of Control” is defined as an event in which the Company’s shareholders become 60% or less the converted value to common at a ratio of 1:3.5 a. The common stock price was in the range $ 1.69 1.12 b. The calculated weighted average number of shares of common stock in the period; c. A 26.63 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.71 10.76 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 4.00 3.84 f. 36.95 34.72 85.39 80.76 0.45 0.60 For the nine months ended March 31, 2017, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 17,148 2.04 17,148 1.75 11,432 1.40 5,316 32,462 The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 56.99 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.79 % For the three and nine months ended March 31, 2017, the Company’s Board of Directors authorized the issuance of 23,136 59,900 27,000 81,000 For the three and nine months ended March 31, 2017, the Company’s Board of Directors authorized the issuance of 9,648 24,831 11,250 33,750 For the three and nine months ended March 31, 2017 two Holders of the Company’s Series B Debentures elected to receive quarterly interest payable of $ 27,178 107,178 24,266 97,999 On February 8, 2017 two Holders of the Company’s Series B Debentures elected to convert $ 5,000,000 4,335,386 For the three and nine months ended March 31, 2017 the Holder of the Company’s Series C Debentures elected to receive interest of $ 166,667 333,334 149,478 303,088

Stock Warrants

Stock Warrants	9 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 - Stock Warrants Stock Warrants Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2016 6,616,700 $ 4.96 2.55 $ 4,459 Granted 45,728 1.77 3.60 - Outstanding and exercisable at March 31, 2017 6,662,428 $ 4.94 1.57 $ - Of the above warrants, 414,284 June 30, 2017 68,577 June 30, 2018 6,065,247 June 30, 2019 68,592 June 30, 2020 45,728 June 30, 2021

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 - Fair Value Measurement Fair value measurements At March 31, 2017 and June 30, 2016, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at March 31, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ - Derivative liability – Series C debentures - - 50,316 Derivative liability – warrants - - 2,017,476 Total derivatives $ - $ - $ 2,067,792 Fair Value Measurements at June 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 203,030 Derivative liability – Series C debentures - - 343,673 Derivative liability – warrants - - 3,197,182 Total derivatives $ - $ - $ 3,743,885 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,810,071 2,479,935 58,910 76,306 5,425,222 The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of March 31, 2017 and June 30, 2016 with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. 1 Year 3/31/17 70 % 6/30/16 83 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Derivative liability – liability – liability – Series B Series C warrant Beginning balance at July 1, 2016 $ 203,030 $ 343,673 $ 3,197,182 Additions during the year - - - Change in fair value (203,030) (293,357) (1,179,706) Transfer in and/or out of Level 3 - - - Balance at March 31, 2017 $ - $ 50,316 $ 2,017,476

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an employment agreement effective July 1, 2015 for a term of three years. Dr. Diwan’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 The Company and Dr. Seymour, the Company’s Chief Executive Officer and Director, entered into an employment agreement effective July 1, 2015, for a term of three years. Dr. Seymour’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $ 150,000 26,786 35,715 26,786 35,715 On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $ 150,000 35,715 35,715 On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $ 9,000 2,572 10,800 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2016 filed with the SEC on September 16, 2016. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 filed on September 16, 2016.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2017 March 31, 2016 Warrants 6,662,428 6,599,552 Total potentially outstanding dilutive common shares 6,662,428 6,599,552 In addition, the Company has issued Convertible Debentures to investors. At March 31, 2017, pursuant to the redemption provisions of the Company’s Series C Convertible Debenture (the “Series C Debenture”), the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the “Redemption Warrants”, and collectively with (i) – (iv), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. At March 31, 2017, the number of potential dilutive shares of the Company’s common stock into which the Series C debentures can be converted based upon the conversion provisions contained in the debenture is 952,381 The Company has also issued 4,341,028 3.5 60% or less 15,193,598 For the three months ended For the Nine months ended March 31, March 31, 2017 2016 2017 2016 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Basic loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Add: Income impact of assumed conversion of Debentures - - - - Net loss attributable to common stockholders plus assumed conversions $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Incremental shares from assumed conversions of Debentures payable - - - - Denominator for diluted weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Diluted loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16) Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three and nine months ended March 31, 2017 because their inclusion is anti-dilutive. Additionally, the Series A Preferred shares are contingently convertible instruments, where the contingency is not based upon the price of the Company’s stock or the convertible instruments. The necessary conditions for conversion (see above) have not been satisfied and the potential shares are not included pursuant to ASC 260-10-55-44.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company is currently in the process of assessing the impact of the ASU on its financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2017 March 31, 2016 Warrants 6,662,428 6,599,552 Total potentially outstanding dilutive common shares 6,662,428 6,599,552 The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for loss from continuing operations: For the three months ended For the Nine months ended March 31, March 31, 2017 2016 2017 2016 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Basic loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Add: Income impact of assumed conversion of Debentures - - - - Net loss attributable to common stockholders plus assumed conversions $ (3,138,677) $ (4,991,671) $ (7,746,520) $ (9,073,916) Denominator for basic weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Incremental shares from assumed conversions of Debentures payable - - - - Denominator for diluted weighted average shares of common stock 61,002,941 57,836,770 59,115,786 57,565,406 Diluted loss per share of common stock $ (0.05) $ (0.09) $ (0.13) $ (0.16)

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2017 2016 2017 2016 Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 1,589 $ 8,022 $ 19,584 $ 22,670 As of March 31, June 30, 2017 2016 Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs, as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ - $ 767,454 March 31, June 30, 2017 2016 Prepaid Expenses – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour, the Company is obligated to submit payment equivalent of two months of expenses to TheraCour. This payment is provided to fund expenses incurred by TheraCour on our behalf but have not been billed to the Company. The prepayment net of any accounts payable due to TheraCour Pharma Inc. on the reporting date was $ 370,187 $ - For the three months ended For the nine months ended March 31, March 31, March 31, March 31, 2017 2016 2017 2016 Research and Development Costs Paid to Related Parties Development fees and other costs charged by and paid to TheraCour pursuant to an Exclusive License Agreement between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2017 and June 30, 2016 $ 635,591 $ 751,203 $ 2,475,707 $ 2,763,817 As of March 31, June 30, Debentures Payable to a Director 2017 2016 Series B Convertible Debentures - Milton Boniuk $ - $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 5,000,000 Total Debentures Payable to a Director $ 5,000,000 $ 9,000,000 As of March 31, June 30, Debenture Interest Payable to a Director 2017 2016 Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest is paid out quarterly over the remaining term of the debenture commencing September 30, 2015: Deferred interest payable - short-term $ 166,667 $ 166,667 Deferred interest payable - long-term 41,666 166,667 Total Debenture Interest Payable to a Director $ 208,333 $ 333,334

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: March 31, June 30, 2017 2016 GMP Facility $ 7,996,402 $ 7,996,402 Land 260,000 260,000 Office Equipment 48,486 46,897 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,419,708 5,302,677 Total Property and Equipment 13,730,203 13,611,583 Less Accumulated Depreciation (2,340,146) (1,850,816) Property and Equipment, Net $ 11,390,057 $ 11,760,767

Trademark and Patents (Tables)

Trademark and Patents (Tables)	9 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: March 31, June 30, 2017 2016 Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (73,688) (67,487) Trademarks and Patents, Net $ 385,266 $ 391,467

Convertible Debentures and De23

Convertible Debentures and Derivatives (Tables)	9 Months Ended
	Mar. 31, 2017
Series B Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table presents the balance of the Series B Debenture payable, net of discount at June 30, 2016. The Series B debentures matured on February 1, 2017, as described further below. The debt discount has been amortized to interest expense over the term of the debenture: June 30, 2016 Proceeds $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) 3,264,690 Accumulated amortization of debt discount 2,210,047 Debenture payable - Series B, net $ 5,474,737
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at March 31, 2017 and June 30, 2016: March 31, June 30, 2017 2016 Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 1,764,541 1,165,393 Debenture payable - Series C, net $ 3,732,816 $ 3,133,668

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Mar. 31, 2017
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 56.99 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.79 %
Series A Preferred Stock [Member]
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2016 2,572 $ 11,439 8/31/2016 2,572 11,978 9/30/2016 2,572 10,847 10/31/2016 2,572 9,591 11/30/2016 2,572 7,631 12/31/2016 2,572 6,583 1/25/2017 200,000 512,984 1/31/2017 2,572 6,231 2/28/2017 2,572 6,357 3/3/2017 26,786 65,629 3/31/2017 2,572 6,493 249,934 $ 655,763

Stock Warrants (Tables)

Stock Warrants (Tables)	9 Months Ended
	Mar. 31, 2017
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Weighted Exercise Average Price Remaining Aggregate Number of per share Contractual Term Intrinsic Value Stock Warrants Shares ($) (years) ($) Outstanding and exercisable at June 30, 2016 6,616,700 $ 4.96 2.55 $ 4,459 Granted 45,728 1.77 3.60 - Outstanding and exercisable at March 31, 2017 6,662,428 $ 4.94 1.57 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At March 31, 2017 and June 30, 2016 the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at March 31, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ - Derivative liability – Series C debentures - - 50,316 Derivative liability – warrants - - 2,017,476 Total derivatives $ - $ - $ 2,067,792 Fair Value Measurements at June 30, 2016: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 203,030 Derivative liability – Series C debentures - - 343,673 Derivative liability – warrants - - 3,197,182 Total derivatives $ - $ - $ 3,743,885
Schedule Of Projected Annual Volatility [Table Text Block]	The projected annual volatility for the valuation dates are: 1 Year 3/31/17 70 % 6/30/16 83 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended March 31, 2017: Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Derivative liability – liability – liability – Series B Series C warrant Beginning balance at July 1, 2016 $ 203,030 $ 343,673 $ 3,197,182 Additions during the year - - - Change in fair value (203,030) (293,357) (1,179,706) Transfer in and/or out of Level 3 - - - Balance at March 31, 2017 $ - $ 50,316 $ 2,017,476

Organization and Nature of Bu27

Organization and Nature of Business (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2017	Jun. 30, 2016	Feb. 15, 2010
Product Information [Line Items]
Entity Incorporation, State Country Name	Colorado
Entity Incorporation, Date Of Incorporation	Jul. 25, 2000
Business Acquisition, Name of Acquired Entity	Edot-com.com
Business Acquisition, Date of Acquisition Agreement	May 12, 2005
Common stock, shares issued	63,072,333	58,179,699
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Pro rata Basis	4,000
Stock Issued During Period, Shares, New Issues	80,000,000
Common stock, shares issued	100,000,000
Business Acquisition, Percentage of Voting Interests Acquired	80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred Stock, Voting Rights	the rate of nine votes per share
Preferred stock, shares issued			2,000,000
Preferred stock, value			$ 2,000
Convertible Preferred Stock, Terms of Conversion	The Series A Preferred Stock is convertible, only in the event of a change of control of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details) - shares	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,662,428	6,599,552
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,662,428	6,599,552

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Calculation of basic loss per share of common stock:
Net loss attributable to common stockholders	$ (3,138,677)	$ (4,991,671)	$ (7,746,520)	$ (9,073,916)
Denominator for basic weighted average shares of common stock	61,002,941	57,836,770	59,115,786	57,565,406
Basic loss per share of common stock	$ (0.05)	$ (0.09)	$ (0.13)	$ (0.16)
Calculation of diluted loss per share of common stock:
Net loss attributable to common stockholders	$ (3,138,677)	$ (4,991,671)	$ (7,746,520)	$ (9,073,916)
Add: Income impact of assumed conversion of Debentures	0	0	0	0
Net loss attributable to common stockholders plus assumed conversions	$ (3,138,677)	$ (4,991,671)	$ (7,746,520)	$ (9,073,916)
Denominator for basic weighted average shares of common stock	61,002,941	57,836,770	59,115,786	57,565,406
Incremental shares from assumed conversions of Debentures payable	0	0	0	0
Denominator for diluted weighted average shares of common stock	61,002,941	57,836,770	59,115,786	57,565,406
Diluted loss per share of common stock	$ (0.05)	$ (0.09)	$ (0.13)	$ (0.16)

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual) - $ / shares	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,662,428	6,599,552
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of common stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of common stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of common stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,193,598
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Terms Of Conversion	60% or less
Preferred Stock, Shares Issued	4,341,028		4,091,094
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	952,381
Series A converteble preferred shares [Member]
Accounting Policies [Line Items]
Convertible Preferred Stock, Terms Of Conversion	60% or less

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	Feb. 08, 2017	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Financial Condition [Line Items]
Cash and cash equivalents			$ 16,155,085	$ 25,596,376	$ 16,155,085	$ 25,596,376	$ 24,162,185	$ 31,467,748
Retained Earnings (Accumulated Deficit)			$ (72,570,721)		$ (72,570,721)		$ (64,824,201)
Debt Conversion, Original Debt, Amount	$ 5,332,524
Common stock, par value (in dollars per share)	$ 1.23		$ 0.001		$ 0.001		$ 0.001
Gain (Loss) on Extinguishment of Debt	$ 332,524		$ (332,524)	$ 0	$ (332,524)	$ 0
Series B Convertible Debentures [Member]
Financial Condition [Line Items]
Debt Conversion, Original Debt, Amount	$ 5,000,000	$ 5,027,178
Debt Instrument, Maturity Date		Jan. 31, 2017
Debt Conversion, Converted Instrument, Shares Issued	4,335,386
Common stock, par value (in dollars per share)	$ 0.001
Long-term Debt, Excluding Current Maturities, Total	$ 1,000,000		$ 6,000,000		6,000,000
Gain (Loss) on Extinguishment of Debt	5,000,000				$ 332,524
Series B Convertible Debentures [Member] | Interest Payable [Member]
Financial Condition [Line Items]
Debt Conversion, Original Debt, Amount	$ 27,178
Debt Conversion, Converted Instrument, Shares Issued	24,266

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Feb. 08, 2017	Jun. 30, 2016
Research and development	$ 1,559,202	$ 1,067,495	$ 4,272,339	$ 3,427,068
Due to Related Parties	5,000,000		5,000,000			$ 9,000,000
Deferred interest payable - short term	166,667		166,667		$ 27,178	166,667
Deferred interest payable - long term	41,666		41,666			166,667
Series B Convertible Debentures [Member]
Due to Related Parties	0		0			4,000,000
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000		5,000,000			5,000,000
Deferred interest payable - short term	166,667		166,667			166,667
Deferred interest payable - long term	41,666		41,666			166,667
Interest Payable	208,333		208,333			333,334
TheraCour [Member]
Net Account Payable to related party	0		0			767,454
Research and development	635,591	751,203	2,475,707	2,763,817
Property, Plant and Equipment, Additions	1,589	$ 8,022	19,584	$ 22,670
Interest Payable	$ 370,187		$ 370,187			$ 0

Related Party Transactions (D33

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			charge its costs (direct and indirect) plus no more than 30% of a certain portion of direct costs
Other General and Administrative Expense			$ 2,000
Series B Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	$ 27,178	$ 80,000	187,178	$ 240,000
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount					$ 5,000,000
Series C Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	$ 125,000	$ 125,000	$ 375,000	$ 375,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
GMP Facility	$ 7,996,402	$ 7,996,402
Land	260,000	260,000
Office Equipment	48,486	46,897
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,419,708	5,302,677
Total Property and Equipment	13,730,203	13,611,583
Less Accumulated Depreciation	(2,340,146)	(1,850,816)
Property and Equipment, Net	$ 11,390,057	$ 11,760,767

Property and Equipment (Detai35

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 163,611	$ 163,511	$ 489,330	$ 488,997

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(73,688)	(67,487)
Trademarks and Patents, Net	$ 385,266	$ 391,467

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Trademarks And Patents [Line Items]
Amortization			$ 6,201	$ 6,202
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,067	$ 6,201	$ 6,204

Convertible Debentures and De38

Convertible Debentures and Derivatives (Details) - Series B Debentures [Member]	12 Months Ended
	Jun. 30, 2016USD ($)
Proceeds	$ 6,000,000
Debt discount for bifurcated derivative	(2,735,310)
Net Proceeds From Issuance Of Debt	3,264,690
Accumulated amortization of debt discount	2,210,047
Debenture payable - Series B, net	$ 5,474,737

Convertible Debentures and De39

Convertible Debentures and Derivatives (Details 1) - Series C Debentures [Member] - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Proceeds	$ 5,000,000	$ 5,000,000
Net Proceeds From Issuance Of Debt	1,968,275	1,968,275
Accumulated amortization of debt discount	1,764,541	1,165,393
Debenture payable - Series C, net	3,732,816	3,133,668
Embedded Derivative Financial Instruments [Member]
Debt Discount:	(1,879,428)	(1,879,428)
Series A Preferred Stock [Member]
Debt Discount:	$ (1,152,297)	$ (1,152,297)

Convertible Debentures and De40

Convertible Debentures and Derivatives (Details Textual) - USD ($)	Feb. 08, 2017	Jul. 02, 2014	Jan. 31, 2017	Feb. 01, 2013	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Dec. 31, 2016	Feb. 01, 2016	Feb. 01, 2014
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 1.23				$ 0.001		$ 0.001		$ 0.001
Debt Conversion, Converted Instrument, Amount	$ 24,266						$ 5,000,000	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 5.25		$ 5.25
Interest Payable, Current	27,178				$ 166,667		$ 166,667		$ 166,667
Debt Conversion, Original Debt, Amount	5,332,524
Gain (Loss) on Extinguishment of Debt	$ 332,524				(332,524)	$ 0	(332,524)	0
Conversion Price Of Shares Converted	$ 1.1533
Repayments of Convertible Debt	$ 1,000,000						1,000,000	0
Restricted Stock [Member]
Debt Instrument [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance												571,429
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Amortization of Debt Discount (Premium)					$ 89,165	196,074	$ 525,263	570,505
Debt Conversion, Converted Instrument, Shares Issued	4,335,386
Proceeds from Convertible Debt			$ 6,000,000	$ 6,000,000
Debt Instrument, Term				4 years
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Warrants To Be Issued In Fourth Year											571,433
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 3.50		$ 3.50		$ 3.50	$ 3.50
Long-term Debt, Excluding Current Maturities, Total	$ 1,000,000				$ 6,000,000		$ 6,000,000
Share Price					$ 1.12		$ 1.12		$ 1.60
Debt Instrument, Debt Default, Description of Violation or Event of Default							An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time							0.00%		83.00%
Weighted Average Discount Rate, Percent							21.99%
Debt Instrument, Periodic Payment, Interest					$ 13,589	40,000	$ 173,589	200,000
Common Stock Value Issued for Debt instrument Periodic Interest Payment					27,178	80,000	$ 107,178	$ 160,000
Common Stock Shares Number Of Shares Authorized For Issuance							97,999	101,558
Debt Conversion, Original Debt, Amount	5,000,000		5,027,178
Gain (Loss) on Extinguishment of Debt	$ 5,000,000						$ 332,524
Series B Convertible Debentures [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent			$ 0						$ 203,030
Series B Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time							20.00%
Series B Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time							1.00%
Series B Convertible Debentures [Member] | Restricted Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	4,359,652
Series B Convertible Debentures [Member] | Director [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt				$ 4,000,000
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)					$ 208,497	166,919	$ 599,148	$ 570,505
Debt Conversion, Converted Instrument, Shares Issued		187,000
Proceeds from Convertible Debt		$ 1,645,606
Repayments of Other Debt		1,152,297
Debt Instrument, Unamortized Discount		1,152,297
Debt Conversion, Converted Instrument, Amount		$ 1,879,428
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)		$ 0.001
Debt Instrument, Convertible, Conversion Price		$ 5.25
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Convertible, Carrying Amount of Equity Component		$ 5,000,000
Redemption On Debentures		952,381
Warrants to purchase of Common Stock		619,048
Common stock exercise price		$ 6.05
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 6.05		$ 6.05		$ 6.05
Long-term Debt, Excluding Current Maturities, Total					$ 5,000,000		$ 5,000,000		$ 5,000,000
Share Price			$ 1.60
Debt Instrument, Debt Default, Description of Violation or Event of Default							An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Projected Redemption Percentage Of Time							70.00%		83.00%
Weighted Average Discount Rate, Percent							21.99%
Closing Common Stock Bid Price		$ 5.25
Additional Interest Rate For Warrants		7.00%			7.00%		7.00%
Interest Payable, Current					$ 166,667		$ 166,667		$ 166,667
Interest Payable					208,333		208,333		333,334
Debt Instrument, Periodic Payment, Interest					125,000		125,000	125,000
Common Stock Value Issued for Debt instrument Periodic Interest Payment					$ 41,667	$ 41,667	$ 83,334	$ 41,667
Common Stock Shares Number Of Shares Authorized For Issuance					149,478	69,736	303,088	211,220
Series C Convertible Debenture [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent					$ 50,316		$ 50,316		$ 343,673
Series C Convertible Debenture [Member] | Debenture Interest Paid [Member]
Debt Instrument [Line Items]
Interest Payable, Current					166,667		166,667
Interest Payable					$ 500,000		$ 500,000

Equity Transactions (Details)

Equity Transactions (Details) - Series A Preferred Stock [Member]	9 Months Ended
	Mar. 31, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	249,934
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 655,763
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 11,439
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 11,978
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 10,847
Issuance Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 9,591
Issuance Date Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 7,631
Issuance Date Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,583
Issuance Date Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	200,000
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 512,984
Issuance Date Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,231
Issuance Date Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,357
Issuance Date Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	26,786
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 65,629
Issuance Date Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,493

Equity Transactions (Details 1)

Equity Transactions (Details 1) - Scientific Advisory Board [Member]	9 Months Ended
	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Expected volatility	56.99%
Expected annual rate of quarterly dividends	0.00%
Risk-free rate(s)	1.79%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	Feb. 08, 2017	Jul. 21, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016
Class of Stock [Line Items]
Fair Value Adjustment of Warrants					$ 0	$ 56,115
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.25		$ 5.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							75,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			71,430		71,430
Employee Benefits and Share-based Compensation			$ 597,694		$ 655,763
Non Cash Compensation Expenses			82,145		82,145
Consulting expense [Member]
Class of Stock [Line Items]
Fair Value Adjustment of Warrants			$ 5,316		$ 32,462
Warrant [Member] | August 2020 [Member]
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants					17,148
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.04		$ 2.04
Warrant [Member] | November 2020 [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					17,148
Shares Issued, Price Per Share			1.75		$ 1.75
Warrant [Member] | February 2021 [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					11,432
Shares Issued, Price Per Share			$ 1.40		$ 1.40
Director [Member]
Class of Stock [Line Items]
Share-based Compensation, Total			$ 11,250		$ 33,750
Restricted common stock authorized for interest payable			9,648		24,831
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		225,000
Share-based Compensation, Total			$ 74,317	$ 77,336	$ 222,960	232,008
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			341,460		341,460
President [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		75,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		225,000
Share-based Compensation, Total			74,317	$ 77,336	222,960	$ 232,008
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			341,460		341,460
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		75,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services			$ 27,000		$ 81,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			234,502		249,934
Convertible Preferred Stock, Terms Of Conversion					60% or less
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Restricted Common Stock Value Issued for Debt Instrument Periodic Interest Payment			$ 27,178		$ 107,178
Restricted Common Stock Shares Number Of Shares Authorized For Issuance	4,335,386
Series B Convertible Preferred Stock [Member] | Director [Member]
Class of Stock [Line Items]
Restricted Common Stock Shares Number Of Shares Authorized For Issuance			24,266		97,999
Restricted Common Stock Value Debt Instrument	$ 5,000,000
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Restricted Common Stock Value Issued for Debt Instrument Periodic Interest Payment			$ 166,667		$ 333,334
Series C Convertible Preferred Stock [Member] | Director [Member]
Class of Stock [Line Items]
Restricted Common Stock Shares Number Of Shares Authorized For Issuance			149,478		303,088
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Description					the converted value to common at a ratio of 1:3.5
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage					26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					4 years
Convertible Preferred Stock, Terms Of Conversion					The Series A Preferred Stock is convertible, only in the event of a change of control of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Price			$ 1.12		$ 1.12
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage					10.71%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					3 years 10 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions					34.72%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					80.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					0.45%
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Price			$ 1.69		$ 1.69
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage					10.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions					36.95%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate					85.39%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate					0.60%
Series A Preferred Stock [Member] | Employee Compensations [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services			23,136		59,900

Stock Warrants (Details)

Stock Warrants (Details) - Stock Options [Member] - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	6,616,700
Number of Shares, Granted	45,728
Number of Shares, Outstanding	6,662,428	6,616,700
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.96
Weighted Average Exercise Price per share, Granted (dollars per share)	1.77
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.94	$ 4.96
Weighted Average Remaining Contractual Term (years), Granted	3 years 7 months 6 days
Weighted Average Remaining Contractual Term (years), Outstanding	1 year 6 months 25 days	2 years 6 months 18 days
Aggregate Intrinsic Value, Outstanding (in dollars)		$ 4,459
Aggregate Intrinsic Value, Granted (in dollars)	$ 0
Aggregate Intrinsic Value, Exercised (in dollars)	$ 0

Stock Warrants (Details Textual

Stock Warrants (Details Textual)	9 Months Ended
	Mar. 31, 2017shares
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	414,284
Warrants Expiration Date	Jun. 30, 2017
June 30, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,577
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	6,065,247
Warrants Expiration Date	Jun. 30, 2019
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,592
Warrants Expiration Date	Jun. 30, 2020
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	45,728
Warrants Expiration Date	Jun. 30, 2021

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Warrant [Member]
Derivative Liability, Noncurrent	$ 2,017,476	$ 3,197,182
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	2,067,792	3,743,885
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	203,030
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	50,316	343,673
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 2,017,476	$ 3,197,182

Fair Value Measurement (Detai47

Fair Value Measurement (Details 1)	9 Months Ended
	Mar. 31, 2017
One Year Ended 6/30/2016
Fair Value Assumptions, Expected Volatility Rate	83.00%
One Year Ended 3/31/17
Fair Value Assumptions, Expected Volatility Rate	70.00%

Fair Value Measurement (Detai48

Fair Value Measurement (Details 2)	9 Months Ended
	Mar. 31, 2017USD ($)
Derivative liability - Series C debentures [Member]
Beginning balance	$ 343,673
Additions during the year	0
Change in fair value	(293,357)
Transfer in and/or out of Level 3	0
Ending Balance	50,316
Derivative liability - Series B debentures [Member]
Beginning balance	203,030
Additions during the year	0
Change in fair value	(203,030)
Transfer in and/or out of Level 3	0
Ending Balance	0
Warrant [Member]
Beginning balance	3,197,182
Additions during the year	0
Change in fair value	(1,179,706)
Transfer in and/or out of Level 3	0
Ending Balance	$ 2,017,476

Fair Value Measurement (Detai49

Fair Value Measurement (Details Textual) - $ / shares	1 Months Ended
	Jan. 24, 2014	Sep. 12, 2013	Mar. 31, 2017
Class of Warrant or Right, Outstanding	2,479,935	2,810,071
Warrants Issued	2,479,935	2,945,428
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.25
Placement Agents [Member]
Warrants Issued	76,306	58,910
Warrant Expiration Term	5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.05	$ 5.25
Scientific Advisory Board [Member]
Class of Warrant or Right, Outstanding			5,425,222

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended				9 Months Ended	12 Months Ended
	Jul. 21, 2015	Jan. 31, 2015	May 30, 2013	Mar. 31, 2010	Mar. 31, 2017	Jun. 30, 2016	Feb. 15, 2010
Commitments and Contingencies [Line Items]
Common stock, shares issued					63,072,333	58,179,699
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued							2,000,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					3 years
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 350,000
Chief Executive Officer [Member] | Year One [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					375,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 400,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					225,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term				4 years
Common stock, shares issued				35,715
Additional Common Stock Shares Issued				35,715
Increase In Base Salary				$ 150,000
President [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term					3 years
President [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
President [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 350,000
President [Member] | Year One [Member] | Deferred Bonus [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount					75,000
President [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					375,000
President [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense					$ 400,000
President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					225,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term				4 years
Common stock, shares issued				35,715
Additional Common Stock Shares Issued				35,715
Increase In Base Salary				$ 150,000
Vice President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued				26,786
Additional Preferred Stock Shares Issued				26,786
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term			3 years
Increase In Base Salary		$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued			2,572